2026 ICD-10-CM Diagnosis Code D26.7Other benign neoplasm of other parts of uterus

ICD-10-CM CodesC00–D49D10-D36D26

ICD-10-CM D26.7
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

D26.7 is a billable ICD-10-CM diagnosis code for other benign neoplasm of other parts of uterus. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 742 through 743, 760 through 761. Coders also document this condition as benign neoplasm of placenta. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Benign neoplasms.

Code Identity

ICD-10-CM Code
D26.7
Billable Status
Yes — Valid for Submission
Code Describes
Other benign neoplasm of other parts of uterus
Short Description
Other benign neoplasm of other parts of uterus
Same as the full description in the CMS dataset.
Parent Code
Other benign neoplasms of uterus

Code Classification

ChapterC00–D49Neoplasms
SectionD10-D36Benign neoplasms, except benign neuroendocrine tumors
CategoryD26Other benign neoplasms of uterus
This CodeD26.7Other benign neoplasm of other parts of uterus

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Benign neoplasm of placenta
  • Chorioangioma
  • Neoplasm of placenta

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

External Cause of Injuries IndexGuidance

References for this code in the External Cause of Injuries Index.

    • Chorioangioma

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO073
Benign neoplasms
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Abruptio Placentae

    premature separation of the normally implanted placenta from the uterus. signs of varying degree of severity include uterine bleeding, uterine muscle hypertonia, and fetal distress or fetal death.
  • Annexin A3

    a protein of the annexin family that catalyzes the conversion of 1-d-inositol 1,2-cyclic phosphate and water to 1-d-myo-inositol 1-phosphate.
  • Annexin A4

    protein of the annexin family originally isolated from the electric organ of the electric ray torpedo marmorata. it has been found in a wide range of mammalian tissue where it is localized to the apical membrane of polarized epithelial cells.
  • Annexin A5

    a protein of the annexin family isolated from human placenta and other tissues. it inhibits cytosolic phospholipase a2, and displays anticoagulant activity.
  • Cadherins

    calcium-dependent cell adhesion proteins. they are important in the formation of adherens junctions between cells. cadherins are classified by their distinct immunological and tissue specificities, either by letters (e- for epithelial, n- for neural, and p- for placental cadherins) or by numbers (cadherin-12 or n-cadherin 2 for brain-cadherin). cadherins promote cell adhesion via a homophilic mechanism as in the construction of tissues and of the whole animal body.
  • Chorionic Villi

    threadlike vascular projections of the chorion. chorionic villi may be free or embedded within the decidua forming the site for exchange of substances between fetal and maternal blood (placenta).
  • Cord Blood Stem Cell Transplantation

    transplantation of stem cells collected from the fetal blood remaining in the umbilical cord and the placenta after delivery. included are the hematopoietic stem cells.
  • Eutheria

    mammals which nourish their young in utero by means of a complex placenta, and give birth to their young alive. they include primates; carnivora, whales; ruminants; bats; and rodents.
  • Folate Receptor 2

    a subtype of gpi-anchored folate receptors that is expressed in placenta and hematopoietic cells.
  • Ichthyosis, X-Linked

    chronic form of ichthyosis that is inherited as a sex-linked recessive trait carried on the x-chromosome and transmitted to the male offspring. it is characterized by severe scaling, especially on the extremities, and is associated with steroid sulfatase deficiency.
  • Perilipin-3

    a perilipin that localizes to lipid droplets; cytoplasm; endosomes; and plasma membrane, especially in macrophages. it functions as a transporter of free fatty acids to lipid droplets to promote their biogenesis and growth. it is also required for the transport of the mannose-6-phosphate receptor from endosomes to the trans-golgi network. its structure consists of four helix bundles that interact with the hydrophobic lipid droplet surface.
  • Placenta

    a highly vascularized mammalian fetal-maternal organ and major site of transport of oxygen, nutrients, and fetal waste products. it includes a fetal portion (chorionic villi) derived from trophoblasts and a maternal portion (decidua) derived from the uterine endometrium. the placenta produces an array of steroid, protein and peptide hormones (placental hormones).
  • Placenta Accreta

    abnormal placentation in which all or parts of the placenta are attached directly to the myometrium due to a complete or partial absence of decidua. it is associated with postpartum hemorrhage because of the failure of placental separation.
  • Placenta Diseases

    pathological processes or abnormal functions of the placenta.
  • Placenta Growth Factor

    an angiogenic protein belonging to the vascular endothelial growth factor family of growth factors originally isolated and cloned from human placental cdna library. there are four isoforms of plgf 1-4 which result from alternative splicing. placenta growth factor is secreted as a glycosylated homodimer which acts as a mitogen for endothelial cells, and its expression is markedly upregulated during hypoxia and in tissue inflammation and cancer.
  • Placenta Previa

    abnormal placentation in which the placenta implants in the lower segment of the uterus (the zone of dilation) and may cover part or all of the opening of the cervix. it is often associated with serious antepartum bleeding and premature labor.
  • Placenta, Retained

    a placenta that fails to be expelled after birth of the fetus. a placenta is retained when the uterus fails to contract after the delivery of its content, or when the placenta is abnormally attached to the myometrium.
  • Placental Circulation

    the circulation of blood, of both the mother and the fetus, through the placenta.
  • Placental Extracts

    extracts prepared from placental tissue; they may contain specific but uncharacterized factors or proteins with specific activities.
  • Placental Function Tests

    methods used for the assessment of placental function.
  • Placental Hormones

    hormones produced by the placenta include chorionic gonadotropin, and placental lactogen as well as steroids (estrogens; progesterone), and neuropeptide hormones similar to those found in the hypothalamus (hypothalamic hormones).
  • Placental Insufficiency

    failure of the placenta to deliver an adequate supply of nutrients and oxygen to the fetus.
  • Placental Lactogen

    a polypeptide hormone of approximately 25 kda that is produced by the syncytiotrophoblasts of the placenta, also known as chorionic somatomammotropin. it has both growth hormone and prolactin activities on growth, lactation, and luteal steroid production. in women, placental lactogen secretion begins soon after implantation and increases to 1 g or more a day in late pregnancy. placental lactogen is also an insulin antagonist.
  • Placentation

    the development of the placenta, a highly vascularized mammalian fetal-maternal organ and major site of transport of oxygen, nutrients, and fetal waste products between mother and fetus. the process begins at fertilization, through the development of cytotrophoblasts and syncytiotrophoblasts, the formation of chorionic villi, to the progressive increase in blood vessels to support the growing fetus.
  • Plasminogen Inactivators

    important modulators of the activity of plasminogen activators. the inhibitors belong to the serpin family of proteins and inhibit both the tissue-type and urokinase-type plasminogen activators.
  • Pregnancy Proteins

    proteins produced by organs of the mother or the placenta during pregnancy. these proteins may be pregnancy-specific (present only during pregnancy) or pregnancy-associated (present during pregnancy or under other conditions such as hormone therapy or certain malignancies.)
  • Pregnancy Trimester, First

    the beginning third of a human pregnancy, from the first day of the last normal menstrual period (menstruation) through the completion of 14 weeks (98 days) of gestation.
  • S100 Calcium-Binding Protein A4

    an s100 protein characterized by four helix bundles that form n- and c-terminal ef hand motifs. it functions as a homodimer and interacts with both intracellular and extracellular signaling proteins. aberrant s100a4 activity is associated with neoplasm metastasis; fibrosis; and rheumatoid arthritis.
  • Trophoblastic Tumor, Placental Site

    an uncommon variant of choriocarcinoma. it is composed almost entirely of mononuclear cytotrophoblasts (trophoblasts). because its secretion of hcg (chorionic gonadotropin) is low, a large tumor may develop before the hcg can be detected.
  • Umbilical Cord Clamping

    method of placing clamps on the umbilical cord before cutting after birth.

Table of NeoplasmsClinical

Anatomical sites in the Table of Neoplasms that reference this code family.

SiteMalig.
Primary
Malig.
Secondary
Ca
in situ
BenignUncertainUnspec.
fetal membraneC58C79.82D07.0D26.7D39.2D49.59
placentaC58C79.82D07.0D26.7D39.2D49.59

Patient EducationClinical

Benign Tumors

Tumors are abnormal growths in your body. They can be either benign or malignant. Benign tumors aren't cancer. Malignant ones are. Benign tumors grow only in one place. They cannot spread or invade other parts of your body. Even so, they can be dangerous if they press on vital organs, such as your brain.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert D26.7 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
219.8 Benign neo uterus NEC
Exact Match The mapping is direct, with no qualifiers.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About D26.7Overview

Is D26.7 (Other benign neoplasms of uterus) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report other benign neoplasm of other parts of uterus on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does D26.7 group to?

When other benign neoplasm of other parts of uterus is the principal diagnosis on an inpatient stay, it groups to MS-DRG 742, 743, 760, 761, with relative weights from 0.5696 to 1.8348 depending on complications. Higher weights mean higher Medicare reimbursement.

What is the ICD-9 equivalent of D26.7?

Under the General Equivalence Mappings, other benign neoplasm of other parts of uterus converts to ICD-9-CM 219.8 (benign neo uterus NEC). The mapping is a direct match.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.